Clinical Trials Using Fluorine F 18 Fluorthanatrace

Clinical trials are research studies that involve people. The clinical trials on this list are studying Fluorine F 18 Fluorthanatrace. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • Fluorine F 18 Fluorthanatrace PET / CT in Treating Patients with Primary or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET) / computed tomography (CT) works in treating patients ovarian, fallopian tube, or primary peritoneal cancer that is primary or has come back. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET / CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET / CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Fluorine F 18 Fluorthanatrace PET / CT in Measuring PARP-1 Expression in Patients with Prostate Cancer

    This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET) / computed tomography (CT) works in measuring PARP-1 expression in patients with prostate cancer. Fluorine F 18 fluorthanatrace PET / CT may help doctors to better understand the function of PARP-1 and determine the best way to use imaging to help study new treatments that target the PARP-1 enzyme.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Fluorine F 18 Fluorthanatrace PET / MRI in Measuring Poly (ADP-Ribose) Polymerase Activity in Patients with Cancer

    This early phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography / magnetic resonance imaging (PET / MR) imaging works in measuring poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) in patients with cancer. PARP is a deoxyribonucleic acid (DNA) repair enzyme that enables normal cell survival as well as certain cancers. Diagnostic procedures, such as fluorine F 18 fluorthanatrace PET / MRI may help accurately measure PARP activity in patients with cancer. Measuring tumoral PARP activity levels before and after treatment may help determine which patients are good candidates for PARP inhibitor therapy and confirm that adequate doses of PARP inhibitors are administered to patients.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Evaluating PARP-1 Activity Using 18F-FluorThanatrace PET / CT Scans in Patients with Pancreatic Adenocarcinoma

    This pilot, early phase I trial studies how well 18F-FluorThanatrace positron emission tomography / computed tomography (PET / CT) scans work before and after treatment in identifying PARP-1 activity in patients with pancreatic adenocarcinoma. PARP-1 is a type of enzyme (protein) that helps with different functions of cells, including growth, cell death, recognizing deoxyribonucleic acid (DNA) damage, and DNA repair. 18F-FluorThanatrace is a type of drug called a radioactive tracer that is injected into the body to trace PARP-1 activity in a tumor during an imaging study. 18F-FluorThanatrace PET / CT scans may help researchers understand how PARP-1 functions as well as determine the best way to use imaging to study treatments that target PARP-1.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Fluorine F 18 Fluorthanatrace Biodistribution, Metabolism and Excretion Analysis in Patients with Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    This pilot phase I trial studies fluorine 18 (F 18) fluorthanatrace biodistribution (to see how it is taken up in the body), metabolism and excretion analysis in patients with ovarian, fallopian tube or primary peritoneal cancer. Fluorine F 18 fluorthanatrace is a radioactive substances that are absorbed by cancerous cells and allow for the cancer to be found using diagnostic procedures such as positron emission tomography (PET) and computed tomography (CT). Poly adenosine diphosphate ribose polymerase (PARP-1) is an enzyme that helps regulate cell process, such as cell growth, cell death and detect deoxyribonucleic acid (DNA) damage. Fluorine F 18 fluorthanatrace may be used to detect PARP-1 activity in tumors. Imaging PARP-1 activity in patients with ovarian, fallopian tube or primary peritoneal cancer may help doctors understand its function and determine the best way to use imaging to help study new treatments that target the PARP-1 enzyme.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • 18F-FluorThanatrace PET / CT in Diagnosing Patients with Primary, Recurrent, or Metastatic Breast Cancer

    This phase I trial studies how well fluorine F 18 fluorthanatrace (18F-FluorThanatrace) positron emission tomography / computed tomography (PET / CT) works in diagnosing patients with breast cancer that is primary, has come back, or has spread to other places in the body. Diagnostic procedures, such as 18F-FluorThanatrace PET / CT, may help to find and diagnose breast cancer, find out how far the disease has spread, and may help measure a patient's response to earlier treatment.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania